Amgen 20190341 - Clinical Trial
Who Can Participate in the Study?
Age Group
Adults
Study Details
Full Title
A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non?Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C (20190341, CodeBreaK 202)
Principal Investigator
Medical Oncologist
Protocol Number
IRB:
PRO00113294
NCT:
NCT05920356
Phase
Phase
III
ClinicalTrials.gov
View on ClinicalTrials.gov
Enrollment Status
Open for Enrollment